New hope for kids with MS: safer drug combo under trial
NCT ID NCT07483632
First seen Mar 25, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This study tests two oral drugs, diroximel fumarate and dimethyl fumarate, in children with relapsing multiple sclerosis. About 185 kids will be split by weight and randomly assigned to one of the drugs or a standard treatment (fingolimod). The goal is to see which drug better controls relapses and brain lesions while being safe. The study lasts up to 4 years, including an extension where all kids receive diroximel fumarate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING FORMS OF MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.